The purchase price will be approximately $117 million in cash. The current equity holders of BioArray intend to form a new company prior to closing, to commercialize BioArray technologies in fields outside of blood transfusion and transplantation. In connection with its acquisition of BioArray, Immucor will receive a 19% ownership interest in this new company.
Gioacchino De Chirico, president and CEO of Immucor, said: “This is a landmark acquisition for Immucor which will enable us to provide innovative molecular diagnostic solutions for blood transfusions that complement our current product line. This acquisition also opens up broader opportunities for Immucor in transplantation and transfusion-related applications.”